What Does Research Show on BPC-157 and Tendons?

What kind of tendon and ligament research exists on BPC-157?

BPC-157 is a synthetic 15-amino-acid peptide (PubChem CID 9941957, formula C₆₂H₉₈N₁₆O₂₂, molecular weight 1419.5) described in the literature as a partial sequence of a body protection compound isolated from gastric juice (source 6, source 14). Its connective-tissue literature is narrow and specific: a small number of rodent transection models, a handful of cell-culture and explant experiments, and a set of review articles that summarise them.

A 2025 systematic review in HSS Journal screened 544 articles published between 1993 and 2024 and, after removing duplicates and applying its inclusion criteria, retained 36 studies — 35 preclinical and one clinical (source 11). That ratio is the single most useful orientation figure for anyone assessing this literature. The tendon and ligament work described below sits inside that preclinical 35, not inside a body of controlled human trials.

Two structural features of tendon and ligament tissue explain why these models were chosen at all. A 2019 review in Cell and Tissue Research characterised tendon and ligament as hypovascular and hypocellular — sparse in blood supply and in resident cells — which is why recovery in these tissues is slow and why researchers have looked at angiogenic candidates (source 9).

What did rat Achilles tendon transection studies report?

The founding experiment is a 2003 study in the Journal of Orthopaedic Research (source 1). Researchers transected the right Achilles tendon in rats 5 mm proximal to its calcaneal insertion, producing a defect between the cut ends, then administered BPC-157 intraperitoneally once daily at 10 µg, 10 ng or 10 pg per kilogram of body weight, with the first application 30 minutes after surgery. Assessment ran at days 1, 4, 7, 10 and 14.

The authors reported that saline controls showed severely compromised recovery, while the peptide groups showed increased load to failure, increased load to failure per unit area and a higher Young's modulus of elasticity; higher Achilles functional index (AFI) scores; more mononuclear cells and fewer granulocytes on microscopy; and greater formation of fibroblasts, reticulin and collagen. Notably, the same paper reported that BPC-157 had no effect on the growth of cultured cells on its own — its in-vitro effect appeared only when it opposed 4-hydroxynonenal, an aldehyde the authors describe as a negative modulator of tendocyte growth.

That detail matters when reading the rest of the literature. Across several papers the peptide was not reported as a direct proliferative agent but as something that altered a cell's response to stress.

What did research report about tendon-to-bone reattachment?

A 2006 study in the same journal moved from mid-substance tendon to the osteotendinous junction (source 2). Researchers sharply detached the rat Achilles tendon from the calcaneal bone and compared BPC-157 (10 µg, 10 ng or 10 pg/kg), 6α-methylprednisolone (1 mg/kg) and saline, alone and in combination, over 21 days. They reported increased AFI values, increased load to failure, stiffness and elasticity modulus, better organisation of collagen fibres, more advanced vascular appearance and more type I collagen in the peptide groups. The corticosteroid arm consistently worsened the outcome measures, and the authors reported that BPC-157 substantially reduced that corticosteroid-driven deterioration.

A 2008 paper in Inflammation Research examined the first four days after the same tendon-to-bone transection in 72 Wistar albino rats, before collagen deposition begins (source 3). BPC-157 at 10 µg/kg raised AFI values at all time points (p < 0.05), lowered myeloperoxidase activity and inflammatory cell influx, and raised the vascular index. Methylprednisolone at 5 mg/kg also lowered myeloperoxidase activity but reduced new vessel formation and did not change early functional recovery — a dissociation the authors used to argue that the anti-inflammatory and angiogenic effects were separable.

A 2009 paper in the Journal of Physiology and Pharmacology tested the angiogenic half of that claim directly using VEGF, CD34 and factor VIII antibodies in crushed and transected muscle and tendon (source 4). It reported no direct angiogenic effect in cell culture, but modulated angiogenesis and upregulated VEGF expression in vivo.

What has research observed about BPC-157 in ligament models?

The principal ligament study is a 2010 paper in the Journal of Orthopaedic Research that surgically transected the rat medial collateral ligament (MCL) and followed recovery across 90 days (source 5). Its distinguishing feature is route comparison: the peptide was given intraperitoneally (10 µg or 10 ng/kg), per-orally in drinking water (0.16 µg/mL, roughly 12 mL per rat per day), and topically as a thin cream layer (1.0 µg in distilled water per gram of neutral cream), each without a carrier. The authors reported consistent functional, biomechanical, macroscopic and histological improvements across all three routes.

Carrier independence is the point most often carried forward. A 2026 review in Pharmaceuticals contrasted BPC-157 with growth factors such as PDGF, TGF-β1, IGF-1, FGF, VEGF and the BMPs, noting that those agents required local delivery with carriers and showed limited or no efficacy at junctional sites, whereas BPC-157 was reported to act systemically or locally without a scaffold or carrier construct (source 13). A 2018 review in Current Pharmaceutical Design had positioned the peptide alongside standard angiogenic growth factors on the same basis (source 8).

What did cell and explant studies report about tendon fibroblasts?

Two mechanistic papers from a Taiwanese group work at the cell level. A 2011 study in the Journal of Applied Physiology reported that BPC-157 accelerated the outgrowth of tendon fibroblasts from rat Achilles tendon explants; did not directly change proliferation by MTT assay; increased cell survival under hydrogen peroxide stress; and increased migration and spreading in a dose-dependent manner, with dose-dependent phosphorylation of FAK and paxillin while total protein amounts were unaltered (source 6).

A 2014 study in Molecules ran cDNA microarray analysis on rat Achilles tendon fibroblasts and identified the growth hormone receptor as one of the most abundantly upregulated genes (source 7). Receptor expression rose dose- and time-dependently at both mRNA and protein level, and adding growth hormone to those cells increased proliferation and activated Janus kinase 2. The authors framed this as a potentiating effect rather than a direct one.

How do the main tendon and ligament studies compare?

What did a 2026 head-to-head comparison with TB-500 report?

The most recent primary study is a 2026 paper in Joint Diseases and Related Surgery that compared BPC-157, synthetic thymosin beta-4 (TB-500) and their combination in 32 male Sprague-Dawley rats aged 12 weeks and weighing roughly 330 g, following standardised Achilles transection and repair (source 12). Groups of eight received BPC-157 at 10 µg/kg/day, TB-500 at 60 µg/kg/day, both, or nothing, intraperitoneally for four weeks.

Its results are more equivocal than the earlier literature. Maximum load to failure was higher in both peptide groups than in controls, but reached statistical significance only for TB-500 (p < 0.05). Total Bonar scores were significantly lower for TB-500 (p = 0.016) and total Movin scores were significantly lower for TB-500 and the combination group (p = 0.017 and p = 0.040). The BPC-157 group showed numerically lower scores that did not reach significance on the total scores. The combination conferred no additional benefit over either peptide alone, which the authors suggested may reflect convergence on shared downstream pathways — a hypothesis they explicitly flagged as requiring further experimental confirmation. Researchers comparing the two compounds may find the companion overview of the TB-500 literature useful alongside this one.

What are the limits of the tendon and ligament evidence?

Four constraints define this body of work, and each is stated by the reviewers themselves rather than inferred here.

Species and design

Nearly all of it is rat transection surgery. The 2019 Cell and Tissue Research review noted that the majority of studies were performed on small rodent models and that efficacy in humans was yet to be confirmed (source 9).

Concentration of authorship

The same review observed that across roughly two decades only a handful of research groups had performed in-depth work on the peptide — a replication profile that is thin relative to the volume of positive findings (source 9).

Evidence level

The 2025 systematic review classified the retained literature as level IV and level V, with 35 of 36 studies preclinical. Its single clinical entry was a retrospective report on intra-articular injection for unspecified chronic knee pain in which 7 of 12 individuals reported relief beyond six months — not a controlled trial (source 11).

Regulatory and safety status

That same review recorded that BPC-157 lacks US Food and Drug Administration approval and is banned in professional sport, that it is metabolised in the liver with a reported half-life under 30 minutes and cleared renally, and that while preclinical work showed no adverse effects across several organ systems, no clinical safety data were found (source 11). A 2024 narrative review in the Yale Journal of Biology and Medicine placed peptide approaches to soft-tissue regeneration generally as still in their infancy, with bioavailability and absorption limits by both oral and intra-articular route (source 10).

For laboratory work, the practical consequence is that these figures describe rodent models under controlled conditions and do not transfer to any other setting. What is reproducible from the researcher's side is the material itself: Steadfast Research Group ships each BPC-157 lot with a batch-matched Certificate of Analysis identifying the compound and its measured purity, so that a study using it can state what was actually in the vial. Comparability between experiments starts with identity and purity documentation, not with the published effect sizes above.